



**Australian Government**

---

**Department of Health**

**SCHEDULE OF PHARMACEUTICAL  
BENEFITS**

**EFFICIENT FUNDING OF CHEMOTHERAPY  
SECTION 100 – ARRANGEMENTS SUPPLEMENT**

**SUMMARY OF CHANGES**

**EFFECTIVE 1 MARCH 2014**

## Deletions

### Deletion – Brand

4309T	<i>Pfizer Australia Pty Ltd, PF</i> – <b>Carboplatin</b> , carboplatin 150 mg/15 mL injection, 1 x 15 mL vial
7222D	<i>Pfizer Australia Pty Ltd, PF</i> – <b>Carboplatin</b> , carboplatin 150 mg/15 mL injection, 1 x 15 mL vial
4319H	<i>Pfizer Australia Pty Ltd, PF</i> – <b>Cisplatin</b> , cisplatin 50 mg/50 mL injection, 1 x 50 mL vial
	<i>Pfizer Australia Pty Ltd, PF</i> – <b>Cisplatin</b> , cisplatin 100 mg/100 mL injection, 1 x 100 mL vial
7224F	<i>Pfizer Australia Pty Ltd, PF</i> – <b>Cisplatin</b> , cisplatin 50 mg/50 mL injection, 1 x 50 mL vial
	<i>Pfizer Australia Pty Ltd, PF</i> – <b>Cisplatin</b> , cisplatin 100 mg/100 mL injection, 1 x 100 mL vial
4375G	<i>Epirubicin Kabi, PK</i> – <b>Epirubicin</b> , epirubicin hydrochloride 50 mg/25 mL injection, 1 x 25 mL vial
7231N	<i>Epirubicin Kabi, PK</i> – <b>Epirubicin</b> , epirubicin hydrochloride 50 mg/25 mL injection, 1 x 25 mL vial
4393F	<i>AS-Fludarabine, YA</i> – <b>Fludarabine</b> , fludarabine phosphate 50 mg/2 mL injection, 1 x 2 mL vial
7233Q	<i>AS-Fludarabine, YA</i> – <b>Fludarabine</b> , fludarabine phosphate 50 mg/2 mL injection, 1 x 2 mL vial
4439P	<i>Gemcitabine Kabi, PK</i> – <b>Gemcitabine</b> , gemcitabine 200 mg injection, 1 x 200 mg vial
	<i>Gemcitabine Kabi, PK</i> – <b>Gemcitabine</b> , gemcitabine 2 g injection, 1 x 2 g vial
	<i>Gemcitabine-AS, YA</i> – <b>Gemcitabine</b> , gemcitabine 200 mg/20 mL injection, 1 x 20 mL vial
	<i>Gemcitabine-AS, YA</i> – <b>Gemcitabine</b> , gemcitabine 1 g/100 mL injection, 1 x 100 mL vial
7246J	<i>Gemcitabine Kabi, PK</i> – <b>Gemcitabine</b> , gemcitabine 200 mg injection, 1 x 200 mg vial
	<i>Gemcitabine Kabi, PK</i> – <b>Gemcitabine</b> , gemcitabine 2 g injection, 1 x 2 g vial
	<i>Gemcitabine-AS, YA</i> – <b>Gemcitabine</b> , gemcitabine 200 mg/20 mL injection, 1 x 20 mL vial
	<i>Gemcitabine-AS, YA</i> – <b>Gemcitabine</b> , gemcitabine 1 g/100 mL injection, 1 x 100 mL vial
4451G	<i>Irinotecan Kabi, PK</i> – <b>Irinotecan</b> , irinotecan hydrochloride trihydrate 40 mg/2 mL injection, 1 x 2 mL vial
7249M	<i>Irinotecan Kabi, PK</i> – <b>Irinotecan</b> , irinotecan hydrochloride trihydrate 40 mg/2 mL injection, 1 x 2 mL vial
4514N	<i>Pfizer Australia Pty Ltd, PF</i> – <b>Mitozantrone</b> , mitozantrone 20 mg/10 mL injection, 1 x 10 mL vial
7252Q	<i>Pfizer Australia Pty Ltd, PF</i> – <b>Mitozantrone</b> , mitozantrone 20 mg/10 mL injection, 1 x 10 mL vial
4542C	<i>Oxaliplatin Kabi, PK</i> – <b>Oxaliplatin</b> , oxaliplatin 50 mg/10 mL injection, 1 x 10 mL vial
7253R	<i>Oxaliplatin Kabi, PK</i> – <b>Oxaliplatin</b> , oxaliplatin 50 mg/10 mL injection, 1 x 10 mL vial
4567J	<i>Taxol, BQ</i> – <b>Paclitaxel</b> , paclitaxel 30 mg/5 mL injection, 1 x 5 mL vial
	<i>Taxol, BQ</i> – <b>Paclitaxel</b> , paclitaxel 100 mg/16.7 mL injection, 1 x 16.7 mL vial
	<i>Taxol, BQ</i> – <b>Paclitaxel</b> , paclitaxel 300 mg/50 mL injection, 1 x 50 mL vial
	<i>Paclitaxel Kabi, PK</i> – <b>Paclitaxel</b> , paclitaxel 100 mg/16.7 mL injection, 1 x 16.7 mL vial
7254T	<i>Taxol, BQ</i> – <b>Paclitaxel</b> , paclitaxel 30 mg/5 mL injection, 1 x 5 mL vial
	<i>Taxol, BQ</i> – <b>Paclitaxel</b> , paclitaxel 100 mg/16.7 mL injection, 1 x 16.7 mL vial
	<i>Taxol, BQ</i> – <b>Paclitaxel</b> , paclitaxel 300 mg/50 mL injection, 1 x 50 mL vial
	<i>Paclitaxel Kabi, PK</i> – <b>Paclitaxel</b> , paclitaxel 100 mg/16.7 mL injection, 1 x 16.7 mL vial

## Alterations

### Alteration – Manufacturer's Code

		<i>From</i>	<i>To</i>
7281F	<i>AS-Docetaxel, AF</i> – <b>Docetaxel</b> , docetaxel 80 mg/2 mL injection, vial [1 x 2 mL vial] (& inert substance diluent [1 vial], 1 pack	YA	AF
7282G	<i>AS-Docetaxel, AF</i> – <b>Docetaxel</b> , docetaxel 80 mg/2 mL injection, vial [1 x 2 mL vial] (& inert substance diluent [1 vial], 1 pack	YA	AF
7283H	<i>AS-Docetaxel, AF</i> – <b>Docetaxel</b> , docetaxel 80 mg/2 mL injection, vial [1 x 2 mL vial] (& inert substance diluent [1 vial], 1 pack	YA	AF
7284J	<i>AS-Docetaxel, AF</i> – <b>Docetaxel</b> , docetaxel 80 mg/2 mL injection, vial [1 x 2 mL vial] (& inert substance diluent [1 vial], 1 pack	YA	AF
7285K	<i>AS-Docetaxel, AF</i> – <b>Docetaxel</b> , docetaxel 80 mg/2 mL injection, vial [1 x 2 mL vial] (& inert substance diluent [1 vial], 1 pack	YA	AF
5581R	<i>AS-Docetaxel, AF</i> – <b>Docetaxel</b> , docetaxel 80 mg/2 mL injection, vial [1 x 2 mL vial] (& inert substance diluent [1 vial], 1 pack	YA	AF
5582T	<i>AS-Docetaxel, AF</i> – <b>Docetaxel</b> , docetaxel 80 mg/2 mL injection, vial [1 x 2 mL vial] (& inert substance diluent [1 vial], 1 pack	YA	AF
5583W	<i>AS-Docetaxel, AF</i> – <b>Docetaxel</b> , docetaxel 80 mg/2 mL injection, vial [1 x 2 mL vial] (& inert substance diluent [1 vial], 1 pack	YA	AF
5584X	<i>AS-Docetaxel, AF</i> – <b>Docetaxel</b> , docetaxel 80 mg/2 mL injection, vial [1 x 2 mL vial] (& inert substance diluent [1 vial], 1 pack	YA	AF
5585Y	<i>AS-Docetaxel, AF</i> – <b>Docetaxel</b> , docetaxel 80 mg/2 mL injection, vial [1 x 2 mL vial] (& inert substance diluent [1 vial], 1 pack	YA	AF
7260D	<i>Topotecan Agila, AF</i> – <b>Topotecan</b> , topotecan 4 mg injection, 1 x 4 mg vial	YA	AF
4617B	<i>Topotecan Agila, AF</i> – <b>Topotecan</b> , topotecan 4 mg injection, 1 x 4 mg vial	YA	AF

## Advance Notices

### Advance Notices – Deletion of Item

The following item will be deleted from the Schedule of Pharmaceutical Benefits on 1 April 2014:

5986C **Tropisetron**, tropisetron 5 mg capsule, 2 (*Navoban*)

### Advance Notices – Deletion of Brand

The following brand will be deleted from the Schedule of Pharmaceutical Benefits on 1 April 2014:

5987D *Navoban, NV* – **Tropisetron**, tropisetron 5 mg/5 mL injection, 1 x 5 mL ampoule